Shots:

• The 1st patient has been dosed in the P-Ib/II (REACH) trial that consists of a dose-escalation & dose-expansion portion to evaluate ATG-016 monothx. in patients with advanced solid tumors. The patient's enrollment is ongoing
• The dose-escalation will determine the MTD, RP2D & biologically effective dose of ATG-016 while the dose-expansion portion will initiate the P-II study to assess the efficacy & safety of ATG-016 monothx. for penile SCCs or Stage IV NPC
• In the P-I study, the therapy showed a preliminary anti-tumor activity for advanced solid tumors & hematologic malignancies while the inhibitory effect on the growth of cancer induced by viruses i.e., EBV & HPV in preclinical studies

Ref: PR Newswire | Image: Antegene